on July 21, 2026
The management of metabolic syndrome and prediabetes represents a crucial moment of primary prevention in modern endocrinology. Prediabetes is not a simple static condition, but rather a dynamic disorder characterized by impaired fasting glucose (IFG) or reduced carbohydrate tolerance (IGT), driven by peripheral insulin resistance and progressive pancreatic beta-cell dysfunction. In this scenario, complementing lifestyle changes with an integrated approach based on titrated and standardized plant extracts allows for synergistic action on multiple molecular pathways: from the deceleration of intestinal carbohydrate absorption to the modulation of cellular receptors and lipid profiles.
Intestinal α-Amylase Inhibition and Postprandial Peak Control: Phaseolus vulgaris Extract
The seeds of Phaseolus vulgaris (common bean) contain 2 to 4 g/kg of "non-fiber" compounds capable of slowing glucose absorption in the small intestine by specifically inhibiting the α-amylase enzyme. Experimentally, the administration of P. vulgaris (PVe) extract in obese animal models has demonstrated a significant reduction in caloric intake, with a consequent weight loss and improvement in the postprandial glucose curve [5].
The starch-blocking activity is attributable to α-amylase-inhibiting lectins (phytohemagglutinin and arcelines). Phytohemagglutinin binds to the ciliated epithelium of the intestine, stimulating the endogenous release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), two anorexigenic hormones central to satiety regulation. Although many plant-derived α-amylase inhibitors show high in vitro efficacy but inconsistent in vivo results, purified white bean extract has confirmed its validity in both contexts at doses free of side effects such as diarrhea. The partially purified extraction of the active protein, phaseolamin, shows an inhibition ratio for which 1 g of the substance is able to block the conversion of approximately 454 g of complex carbohydrates (equal to approximately 1800 kcal), maintaining a high tolerability profile up to doses of 7 g/administration.
Since α-amylase inhibition occurs according to a 1:1 molecular stoichiometric ratio relative to the secreted enzyme, efficacy is optimized when the meal presents balanced proportions of carbohydrates, proteins, and fats. In clinical practice, standardized dry extracts of Phaseolus vulgaris (with an inhibitory capacity equal to 1400 U/mg) combined with barley fiber (titrated to 25% in β-glucans) allow for the daily intake of 4 g of soluble fiber and 100 mg of PVe (equal to 6 mg of pure phaseolamin). A study conducted on humans has shown that the administration of P. vulgaris extract significantly reduces the area under the curve of plasma glucose, insulin, and peptide-C compared to the control meal [7]. Considering that the estimated safety levels (NOAEL) are equal to approximately 3 g/day in humans (with a safety factor equal to 30) [8], the dosage of mg at main meals is configured as an effective and risk-free intervention.
Energy Signal Modulation and Lipid Profile Control: Berberine
Berberine, an isoquinoline alkaloid extracted mainly from the rhizome of Berberis aristata [18], offers a pleiotropic action profile capable of simultaneously impacting dyslipidemia and insulin resistance.
On the lipid metabolism side, berberine reduces LDL cholesterol and plasma triglycerides by 25% and 35% respectively [19]. The mechanism of action is post-receptor and distinct from that of statins: it stabilizes the mRNA of the hepatic LDL receptor (LDLR), increasing its expression on the cell surface and increasing the clearance of circulating cholesterol. In parallel, berberine inhibits the PCSK9 protein, the enzyme responsible for the lysosomal degradation of LDLR receptors [20]. Since conventional hypolipidemic treatments (statins, ezetimibe, fibrates) physiologically tend to induce a compensatory increase in PCSK9 [21], the combination of statin and berberine shows a marked synergy of action confirmed in clinical settings [22].
At the carbohydrate metabolism level, the hypoglycemic effect of berberine is comparable to that of metformin, acting on both fasting and postprandial glucose [23]. The primary molecular pathway lies in the activation of the AMPK enzyme (adenosine monophosphate-activated protein kinase), a sensor of cellular energy status. AMPK activation stimulates the translocation of GLUT4 transporters, increases the expression of insulin receptors, inhibits hepatic gluconeogenesis, and reduces intestinal glucose absorption.
The main pharmacokinetic limitation of the berberine cation is the reduced intestinal bioavailability (<5%). However, the intestinal bacterial flora is able to reduce it to dihydroberberine, an uncharged form with significantly higher absorption, which however tends to spontaneously reoxidize. The presence of substances with antioxidant action (such as silimarinoids) in the formulation allows for the stabilization of dihydroberberine, optimizing the absorption ratio.
A meta-analysis conducted on 14 clinical trials for a total of 1068 patients confirmed the hypoglycemic and hypolipidemic efficacy of berberine both in monotherapy compared to placebo, and in combination with oral antidiabetics, highlighting an excellent safety profile characterized only by mild and transient gastrointestinal disorders (Dong et al., 2012). Trials conducted on populations affected by type 2 diabetes and dyslipidemia under complex pharmacological therapy have shown that the addition of high-bioavailability berberine (co-formulated with silymarin) induces an average reduction of 1% of glycated hemoglobin (HbA1c) and a 15% drop in both LDL and triglycerides.
Saccharide Intestinal Receptor Blockade: Gymnema sylvestre
The hypoglycemic action of Gymnema sylvestre leaves is linked to the presence of gymnemic acids (particularly gymnemic acid A1), a mixture of triterpene glycosides. The mechanism unfolds on two levels:
1. Enteric absorption inhibition: The molecular structure of gymnemic acids presents a high stereochemical analogy with that of glucose. This allows them to bind in a competitive and reversible manner to the intestinal receptors responsible for the absorption of sucrose and glucose, reducing the absorbed portion by up to 50%. A similar receptor blockade occurs at the level of the lingual taste buds, where the administration of Gymnema temporarily abolishes the perception of sweet taste.
2. Peripheral metabolic activation: Gymnema extracts promote the intracellular utilization of glucose and stimulate the enzymatic activity responsible for glycolytic pathways.
Carbohydrate Homeostasis Modulation via Receptor and Adipocyte Pathways: Fraxinus excelsior
The extract obtained from the seeds and fruits of the common ash (Fraxinus excelsior, titrated to 5% in phenolic acids) has shown a marked impact on metabolic control. In a crossover, randomized, double-blind, placebo-controlled clinical study lasting 7 weeks, conducted on 22 overweight or obese subjects subjected to a balanced hypocaloric regimen, the administration of extract (Glucevia) resulted in:
· A reduction of 28.2% in the area under the curve (AUC) of glycemia after oral glucose tolerance tests (OGTT) compared to baseline (p < 0.01).
· A reduction of 14% in glycemia values at 2 hours from OGTT (p < 0.01).
· A significant reduction in serum fructosamine and plasma glucagon levels (p < 0.05).
· A significant increase in the adiponectin/leptin ratio and a concomitant reduction in fat mass (p < 0.01) (Zulet MA et al., Phytomedicine 2014).
The modulation of the adipocyte profile (increase in adiponectin and drop in leptin) and the suppression of inappropriate glucagon secretion make this extract a first-choice remedy in cases of reduced glucose tolerance and insulin resistance associated with visceral adiposity.
Metabolic Detoxification and Fiber Fraction: Taraxacum officinale and Trigonella foenum-graecum
Taraxacum officinale (dandelion), thanks to its high inulin content (20%) and bitter sesquiterpene principles, exerts a choleretic and cholagogue action that decongests the hepatic-renal district. The stimulation of liver function and diuresis facilitates the elimination of intermediate catabolites, supporting the liver parenchyma in the context of metabolic alterations and improving tissue insulin sensitivity. (Clinical note: administration is contraindicated in patients suffering from gastritis, peptic ulcer, or gallstones without medical supervision).
Regarding Fenugreek (Trigonella foenum-graecum), meta-analytical evidence indicates a marked hypoglycemic effect linked to the slowing of gastric emptying and the enzymatic modulation of carbohydrate absorption, accompanied by a favorable trend (although deserving of further structured trials) in the reduction of triglycerides and LDL cholesterol.
Integration and Pharmacological Synergies: Curcuma longa and Salvia officinalis
The use of polyphenol extracts offers key support in countering oxidative stress and low-grade inflammation that characterize insulin resistance.
· Curcumin: In a preliminary clinical study conducted on patients suffering from type 2 diabetes under gliburide therapy, the co-administration of curcumin for 10 days resulted in a significant reduction in blood glucose levels, LDL, VLDL, and triglycerides, accompanied by an increase in HDL cholesterol. The mechanism involves the inhibition of glycoprotein-P (P-gp) and the modulation of the lipid profile, improving overall glycometabolic control without increasing the risk of hypoglycemia (Neerati P et al., Phytother Res 2014).
· Salvia officinalis: The Salvia extract evaluated in a randomized clinical trial on 100 diabetic and dyslipidemic patients under standard therapy (metformin, gliburide, and atorvastatin) demonstrated a statistically significant reduction in fasting glucose, postprandial glucose at 2 hours, glycated hemoglobin (HbA1c), triglycerides, total and LDL cholesterol, together with an increase in HDL cholesterol (p < 0.05), without alterations in liver or kidney function markers (Kianbakht S et al., Int J Mol Cell Med 2016).
BIBLIOGRAPHIC REFERENCES
1. Dong H, Wang N, Zhao L, Lu F. Berberine in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2012;2012:591654.
2. Derosa G, Maffioli P, Cicero AF. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther. 2013;13(11):1495-1503.
3. Di Pierro F, Putignano P, Villanova R, Montano L. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013;5:167-174.
4. Derosa G, D'Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents. 2013;27(3):717-728.
5. Menezes EW, Lajolo FM. Inhibition of starch digestion by a black bean α-amylase inhibitor, in normal and diabetic rats. Nutr Rep Int. 1987;36:1185–1195.
6. Slavin J, Green H. Dietary fibre and satiety. Br Nutr Found Nutr Bull. 2007;32:32-42.
7. Spadafranca A, Rinelli S, Riva A, Morazzoni P, Magni P, Bertoli S, Battezzati A. Phaseolus vulgaris extract affects glycometabolic and appetite control in healthy human subjects. Br J Nutr. 2013;109(10):1789-1795.
8. Chokshi D. Subchronic oral toxicity of a standardized white kidney bean (Phaseolus vulgaris) extract in rats. Food Chem Toxicol. 2007;45(1):32–40.
9. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344–1351.
10. Zulet MA, Navas-Carretero S, Lara Y Sánchez D, Abete I, Flanagan J, Issaly N, et al. A Fraxinus excelsior L. seeds/fruits extract benefits glucose homeostasis and adiposity related markers in elderly overweight/obese subjects: A longitudinal, randomized, crossover, double-blind, placebo-controlled nutritional intervention study. Phytomedicine. 2014;21(10):1162-1169.
11. Neerati P, Devde R, Gangi AK. Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. Phytother Res. 2014;28(12):1796-1800.
12. Kianbakht S, Nabati F, Abasi B. Salvia officinalis (Sage) Leaf Extract as Add-on to Statin Therapy in Hypercholesterolemic Type 2 Diabetic Patients: a Randomized Clinical Trial. Int J Mol Cell Med. 2016;5(3):141-148.
